Veracyte Inc. | Mutual Funds
Mutual Funds that own Veracyte Inc.
ARK Innovation ETF
1,741,251
4.42%
-39,700
1.56%
09/05/2018
ARK Web x.0 ETF
1,260,497
3.2%
0
2.27%
09/05/2018
Catalyst Eventide Gilead Fund
1,203,500
3.05%
0
0.82%
06/29/2018
Eventide Healthcare & Life Sciences Fund
930,000
2.36%
0
1.7%
06/29/2018
ARK Genomic Revolution Multi Sector ETF
870,303
2.21%
4,859
3.57%
09/05/2018
Vanguard Total Stock Market Index Fund
728,154
1.85%
119,880
0%
07/31/2018
iShares Russell 2000 ETF
525,794
1.33%
-282
0.01%
09/06/2018
iShares Nasdaq Biotechnology ETF
456,561
1.15%
-5,964
0.06%
09/06/2018
Vanguard Extended Market Index Fund
376,410
0.95%
115,585
0.01%
07/31/2018
db x-trackers S&P 500 ETF
271,235
0.69%
271,235
0.08%
08/30/2018
| Address |
6000 Shoreline Court
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.veracyte.com |
| Updated |
07/08/2019 |
| Veracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. |
